NSG Bio has signed a memorandum of understanding (MoU) with Charles River Laboratories aimed at strengthening support for biotech companies building and scaling in Singapore. The MoU was signed during Charles River’s APAC Biomanufacturing Leadership Summit 2026, reflecting a shared commitment to accelerating innovation through stronger connections across the life sciences value chain.
The partnership combines NSG Bio’s purpose-built infrastructure and community platform with Charles River’s global life sciences expertise, to enable companies to move more efficiently from early research toward key development milestones. Charles River’s work on cell banking, cell line characterisation, protein characterisation and other testing capabilities brings value to the biotech ecosystem.
“From the beginning, NSG Bio’s main goal has always been simple but important: to empower the biotech community, not only within NSG Bio but also across the broader Singapore ecosystem. We aim to create an environment where scientists and startups have the infrastructure, resources, and support they need to turn ideas into impactful innovations,” said Hasyim Sim, chief operating officer of NSG Bio.
“With the signing of this Memorandum of Understanding with Charles River, we are taking another meaningful step forward. As a leading scientific partner providing a wide range of research and laboratory products and services, Charles River brings tremendous expertise and capabilities to the table. Through this collaboration, NSG BioLabs will be better positioned to support our community end-to-end from infrastructure and tools to specialised services, products, and scientific expertise.”
“We are excited to deepen our partnership with NSG Bio as we continue to support the growth of the biotech industry in Singapore. Utilising our biologics expertise, we help organisations become more efficient as they move from initial research to key development milestones,” said Kerstin Dolph, senior vice president, manufacturing, at Charles River.
Singapore’s life sciences sector continues to attract innovative startups and global industry players. As companies scale, they face increasing complexity across development planning, operational readiness, and execution. NSG Bio and Charles River intend to collaborate on initiatives that help reduce friction for companies and strengthen pathways between early R&D and downstream development activities.
Under the MoU, the parties will explore opportunities including: ecosystem enablement initiatives for biotech companies, like shared learning sessions; a range of characterisation and testing capabilities; knowledge exchange and access to expertise across relevant scientific and industry domains; and opportunities to connect startups with partners and resources that support efficient development and scaling.